Immunogenicity and Protective Capacity of a Virosomal Respiratory Syncytial Virus Vaccine Adjuvanted with Monophosphoryl Lipid A in Mice
PLoS ONE, May 2012 | Volume 7 | Issue 5 | e36812
Respiratory Syncytial Virus (RSV) is a major cause of viral brochiolitis in infants and young children and is also a significant problem in elderly and immuno-compromised adults. According to the WHO, annually 64 million people are infected with RSV, and 160,000 people die from the infection around the world [1]. It is estimated that, each year, RSV leads to 3.4 million hospitalizations of children [2]. By the age of two, nearly all children have been infected with RSV. However, natural infection does not evoke long-lasting immunity, which causes people to undergo multiple RSV infections throughout their lives.
| Media Name | Media Type | Description | Download |
|---|---|---|---|
| Immunogenicity and Protective Capacity of a Virosomal Respiratory Syncytial Virus Vaccine Adjuvanted with Monophosphoryl Lipid A in Mice | Download |